Anaeropharma Science and Chugai Pharmaceutical Co., Ltd. headquartered in Tokyo have concluded a collaborative rese...
A joint research group centered around Professor Hideyuki Okano and Associate Professor Jun Kohyama, Department of Physi...
Daiichi Sankyo Company, recently announced that it has submitted a New Drug Application (NDA) to Japan’s Min...
Eisai Co., Ltd. and Purdue Pharma L.P. announced positive topline results from SUNRISE 2, a long-term Phase 3 efficacy a...
Eisai Co., Ltd. has entered into an agreement with Eurofarma Laboratorios, to grant exclusive development and marketing ...
Hitachi, Ltd. announced that its heavy ion beam therapy system has started treatment at Osaka Heavy Ion Therapy Center a...
Innovus Pharmaceuticals, an emerging commercial-stage pharmaceutical company that delivers safe, innovative and effectiv...
The Global Health Innovative Technology (GHIT) Fund has welcomed Ono Pharmaceutical Co., Ltd. (Ono) to join GHIT as a ne...
A team of scientists from Tohoku University in collaboration with Advantest has developed in vivo skin imaging technolog...
GenAhead and ERS Genomics has announced a non-exclusive license agreement to provide GenAhead with access to ERS Genomic...
US based pharmaceutical company Novan has announced an extended license agreement with Sato Pharmaceutical Co, a Japanes...
Daiichi Sankyo Company, Limited has announced that axicabtagene ciloleucel (formerly KTE-C19) has been granted Orphan Dr...
Orgenesis, a manufacturer, service provider and developer of advanced cell therapies, has announced that it has entered ...
Researchers from Eindhoven University of Technology (The Netherlands) and Keio University (Japan) have developed a pract...
Japanese scientist Tasuku Honjo has been awarded this year’s Nobel Prize in physiology or medicine, for his discov...
Eisai Co., Ltd. has announced that its U.S. subsidiary Eisai Inc. received approval from the U.S. Food and Drug Administ...
The Global Health Innovative Technology (GHIT) Fund, Japan recently announced an investment of approximately 420 million...
Peptidream Inc., a public Kanagawa-based biopharmaceutical company has announced that it has entered into a broad-based ...
